Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series
Juan D Duque-Yemail,Juan Carlos Avila
DOI: https://doi.org/10.2147/NDT.S367922
IF: 2.989
2022-07-14
Neuropsychiatric Disease and Treatment
Abstract:Juan D Duque-Yemail, 1 Juan Carlos Avila 2 1 Psychiatry Resident, Department of Mental Health, Vall d'Hebron University Hospital, Barcelona, Spain; 2 Psychiatrist, Mental Health Center, Badalona, Spain Correspondence: Juan D Duque-Yemail, Vall d'Hebron University Hospital, Department of Mental Health, Antiga Escola d'Infermeria Building, Passeig de la Vall d'Hebron, 119, Barcelona, 08035, Spain, Tel +34 934 89 30 00, Email Despite many available treatments for schizophrenia, several unmet needs persist in treating individuals with this disorder, and the response rate to first-line antipsychotics remains relatively low. Clozapine has shown efficacy in treating schizophrenia patients who failed to respond to previous antipsychotics. However, side effects and the need for routine blood tests have limited its use as a first-line treatment. Cariprazine is a D 2 /D 3 partial agonist antipsychotic with a mechanism of action that differs from other antipsychotics due to its higher affinity for D 3 receptors. Several trials have demonstrated the efficacy of cariprazine on positive and negative symptoms of schizophrenia and have shown that it is a well-tolerated treatment. In this series, we present 3 cases of patients diagnosed with schizophrenia who were initially under treatment with clozapine. Despite some initial improvement, the patients showed persisting positive and negative symptoms or developed limiting side effects while in treatment with clozapine. Cariprazine treatment was titrated concurrently with clozapine tapering until its discontinuation. Significant improvement in both positive and negative symptoms was observed up to 14 months after starting cariprazine, and resolution of side effects was reported in all cases. Our case series supports cariprazine as an effective treatment for positive and negative symptoms in patients who failed to adequately respond or poorly tolerated treatment with clozapine, as well as a potential treatment in dual disorders, specifically psychotic disorders and cocaine use disorder. Keywords: schizophrenia, cariprazine, atypical antipsychotics, clozapine, resistant schizophrenia Schizophrenia is a chronic and severely disabling disorder with a prevalence of 0.5–1.5%, globally. 1,2 Typical symptoms of schizophrenia can be divided into positive, negative, and cognitive domains. Positive symptoms include abnormal thoughts and behaviors such as formal thought disorder, delusions, hallucinations, and disorganized speech and behavior. 1–4 Negative symptoms include social withdrawal, affective blunting, anhedonia, diminished initiative (avolition), and anergy. 1,2,4 Cognitive symptoms are expressed in a wide variety of cognitive dysfunctions, predominantly in attention, memory, and judgment. 1,2,4 The clinical course is typically progressive and deteriorating, with onset usually during late adolescence. 1,2,4 Antipsychotics are the treatment of choice in acute and chronic phases of schizophrenia, which are frequently effective in controlling positive symptoms, with mild-to-moderate efficacy in treating negative symptoms. 5–8 Although all antipsychotics exert their effect by their actions at receptors of the dopamine or serotonin pathway, different drugs have been developed and classified into typical (first-generation) antipsychotics (FGA) and atypical (second-generation) antipsychotics (SGA). 1,7,9 The main differences between FGA and SGA are their target receptors and side effect profile. 9,10 FGA antipsychotics act predominantly via antagonism of D 2 receptors. Both their antipsychotic efficacy and extrapyramidal side effects are thought to be mediated through this mechanism of action. 9,10 SGAs were developed to improve tolerability and enhance their effectiveness in treating negative symptoms of schizophrenia. 10 SGA also act as D 2 receptor antagonists, although their clinical efficacy in positive and negative symptoms and the lower frequency of extrapyramidal side effects are attributable to their 5-HT 2A receptor antagonism. 10 SGAs not only have an affinity for these two receptors but also on other serotonin and dopamine receptors, as well as histaminergic, cholinergic, and adrenergic receptors. 7,10,11 Clozapine was the first atypical antipsychotic developed to treat schizophrenia with the promise of better tolerability, given the absence of extrapyramidal side effects that afflicted patients under treatment with typical antipsychotics. 12,13 This gave people with treatment-refractory schizophrenia a new alternative for a better quality of life. 12 Pharmacodynamic studies indicate that clozapine has a high binding affinity for -Abstract Truncated-
psychiatry,clinical neurology